ReviewMolecular biology reports2026
Microbiome and pancreatic ductal adenocarcinoma: mechanistic insights, microenvironmental interactions, and therapeutic implications.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by late diagnosis, rapid progression, therapeutic resistance, and a highly immunosuppressive tumor microenvironment (TME). Increasing evidence indicates that the microbiome represents an additional layer of host-tumor interaction influencing PDAC development, progression, and treatment response. PDAC-associated dysbiosis involves coordinated alterations across gut, oral, and intratumoral microbial communities, accompanied by functional changes in microbial metabolism and host signaling. Among microbial groups implicated in PDAC, Firmicutes-associated taxa have attracted particular attention because of their metabolic capacity, including short-chain fatty acid (SCFA) production, and their roles in immune regulation and epithelial homeostasis. Microbiota-derived metabolites may exert context-dependent effects on immune remodeling, metabolic reprogramming, stromal regulation, and TME interactions, with potentially tumor-promoting or tumor-suppressive effects. Meanwhile, microbial signatures and metabolite-associated features are being explored as potential diagnostic, prognostic, and predictive biomarkers. Preclinical studies suggest that microbiome-modulating strategies, including ecological restoration, probiotics, fecal microbiota transplantation, and metabolite-based interventions, may influence therapeutic responsiveness. However, current evidence remains largely observational or preclinical, with unresolved challenges involving causality, reproducibility, methodological standardization, and clinical translation. This review summarizes current knowledge of microbiome-pancreas interactions in PDAC, emphasizing Firmicutes-associated microbial functions, immunometabolic mechanisms, biomarker potential, therapeutic implications, and future directions toward microbiome-informed precision strategies.
Indexed as
Identifiers
42640483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.